Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 701–800 of 4,628
Outcome of lung transplantation in idiopathic pulmonary fibrosis with previous anti-fibrotic therapy
Leuschner, G., Stocker, F., Veit, T., Kneidinger, N., Winter, H., Schramm, R., Weig, T., Matthes, S., Ceelen, F., Arnold, P., et al. (2018) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2017.07.002 · Cited by 59
Prasad, J. D., Mahar, A. M., Bleasel, J. F., Ellis, S. J., Chambers, D. C., Lake, F., Hopkins, P. M.-A., Corte, T. J., Allan, H., & Glaspole, I. (2017) · Respirology · doi:10.1111/resp.13163 · Cited by 65
Tzouvelekis, A., Karampitsakos, Τ., Kontou, M., GRANITSAS, A. N., Malliou, I., Anagnostopoulos, A., Ntolios, P., Tzilas, V., Bouros, E., Steiropoulos, P., et al. (2018) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2018.01.006 · Cited by 67
Idiopathic Pulmonary Fibrosis is a Genetic Disease Involving Mucus and the Peripheral Airways
Schwartz, D. A. (2018) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201802-144aw · Cited by 67
He, N., Bai, S., Huang, Y. L., Xing, Y., Chen, L., Yu, F., & Lv, C. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b00713 · Cited by 58
Allocca, M., Fiorino, G., Bonifacio, C., Peyrin‐Biroulet, L., & Danese, S. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.04.025 · Cited by 60
Hoffmann-Vold, A.-M., Weigt, S. S., Saggar, R., Palchevskiy, V., Volkmann, E. R., Liang, L. L., Ross, D., Ardehali, A., Lynch, J. P., & Belperio, J. A. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.10.050 · Cited by 58
“To date, there are no treatment recommendations for ILDs other han IPF and SSc-ILD and only IPF has Food and Drug Adminisration (FDA) approved treatments with Nintedanib being one of hem [5 , 6 , 17–19] .”
BackgroundResultInfluentialWorrell, J. C., & O’Reilly, S. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102526 · Cited by 64
Comparing new treatments for idiopathic pulmonary fibrosis – a network meta-analysis
Loveman, E., Copley, V. R., Scott, D. A., Colquitt, J. L., Clegg, A. J., & O’Reilly, K. M. (2015) · BMC Pulmonary Medicine · doi:10.1186/s12890-015-0034-y · Cited by 58
Fibrosis and cancer: shared features and mechanisms suggest common targeted therapeutic approaches
Landolt, L. Z., Spagnoli, G. C., Hertig, A., Brochériou, I., & Marti, H. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa301 · Cited by 63
Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial
Noth, I., Cottin, V., Chaudhuri, N., Corte, T. J., Johannson, K. A., Wijsenbeek, M. S., Jouneau, S., Michael, A., Quaresma, M., Rohr, K. B., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.01518-2020 · Cited by 71
Self-citationLindell, K. O., Klein, S. J., Veatch, M. S., Gibson, K. F., Kass, D. J., Nouraie, M. S., & Rosenzweig, M. Q. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202012-1494oc · Cited by 67
Enzymatic cross-linking of collagens in organ fibrosis – resolution and assessment
Pehrsson, M., Mortensen, J. H., Manon‐Jensen, T., Bay‐Jensen, A., Karsdal, M. A., & Davies, M. J. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2021.1962711 · Cited by 58
SPP1 induces idiopathic pulmonary fibrosis and NSCLC progression via the PI3K/Akt/mTOR pathway
Yue, B., Xiong, D., Chen, J., Yang, X., Zhao, J., Shao, J., Wei, D., Gao, F., Huang, M., & Chen, J. (2024) · Respiratory Research · doi:10.1186/s12931-024-02989-7 · Cited by 74
Interstitial lung disease in systemic sclerosis
Wells, A. U. (2014) · La Presse Médicale · doi:10.1016/j.lpm.2014.08.002 · Cited by 63
Role of IL-17A in murine models of COPD airway disease
Yanagisawa, H., Hashimoto, M., Minagawa, S., Takasaka, N., Ma, R., Moermans, C., Ito, S., Araya, J., Budelsky, A., Goodsell, A., et al. (2016) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00301.2016 · Cited by 61
Lin, C., Borensztajn, K., & Spek, C. A. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13623 · Cited by 66
Repurposing Pentoxifylline for the Treatment of Fibrosis: An Overview
Wen, W. X., Lee, S. Y., Siang, R., & Koh, R. Y. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0547-2 · Cited by 63
Multidisciplinary evaluation of interstitial lung diseases: current insights
Walsh, S. L. F. (2017) · European Respiratory Review · doi:10.1183/16000617.0002-2017 · Cited by 69
BRD4 inhibition for the treatment of pathological organ fibrosis
Stratton, M. S., Haldar, S. M., & McKinsey, T. A. (2017) · F1000Research · doi:10.12688/f1000research.11339.1 · Cited by 58
PTP4A1 promotes TGFβ signaling and fibrosis in systemic sclerosis
Sacchetti, C., Bai, Y., Stanford, S. M., Benedetto, P. D., Cipriani, P., Santelli, E., Piera-Velázquez, S., Chernitskiy, V., Kiosses, W. B., Ceponis, A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01168-1 · Cited by 62
Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS® trials
Costabel, U., Behr, J., Crestani, B., Stansen, W., Schlenker‐Herceg, R., Stowasser, S., & Raghu, G. (2018) · Respiratory Research · doi:10.1186/s12931-018-0866-0 · Cited by 65
“The design of the INPULSIS® trials has been described [22].”
BackgroundMethodInfluentialSelf-citationKorfei, M., Stelmaszek, D., MacKenzie, B., Skwarna, S., Chillappagari, S., Bach, A., Ruppert, C., Saito, S., Mahavadi, P., Klepetko, W., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0207915 · Cited by 64
Metabolic Reprogramming as a Driver of Fibroblast Activation in PulmonaryFibrosis
Para, R., Romero, F., George, G., & Summer, R. S. (2019) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2019.02.003 · Cited by 67
Mortality Trends of Idiopathic Pulmonary Fibrosis in the United States From 2004 Through 2017
Jeganathan, N., Smith, R. A., & Sathananthan, M. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.08.016 · Cited by 63
Pulmonary fibrosis: Emerging diagnostic and therapeutic strategies
Selvarajah, B., Platé, M., & Chambers, R. C. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101227 · Cited by 57
A New Hope for Idiopathic Pulmonary Fibrosis
Hunninghake, G. M. (2014) · New England Journal of Medicine · doi:10.1056/nejme1403448 · Cited by 57
Self DNA perpetuates IPF lung fibroblast senescence in a cGAS-dependent manner
Schuliga, M. J., Read, J. M., Blokland, K. E. C., Waters, D. W., Burgess, J. K., Prêle, C. M., Mutsaers, S. E., Jaffar, J., Westall, G. P., Reid, A. T., et al. (2020) · Clinical Science · doi:10.1042/cs20191160 · Cited by 62
“some patients, do not reverse fibrosis, are expensive and have significant side-effects [3, 4].”
BackgroundDeep learning in interstitial lung disease—how long until daily practice
Trușculescu, A. A., Manolescu, D., Tudorache, E., & Oancea, C. I. (2020) · European Radiology · doi:10.1007/s00330-020-06986-4 · Cited by 68
Sun, J., Jin, T., Su, W., Guo, Y., Niu, Z., Guo, J., Li, L., Wang, J., Ma, L., Yu, T., et al. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-021-00792-1 · Cited by 60
Distinct roles of KLF4 in mesenchymal cell subtypes during lung fibrogenesis
Chandran, R. R., Xie, Y., Gallardo‐Vara, E., Adams, T. S., García-Milian, R., Kabir, I., Sheikh, A. Q., Kaminski, N., Martin, K. A., Herzog, E. L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27499-8 · Cited by 60
Chae, K. J., Chung, M. J., Jin, G. Y., Song, Y. J., An, A. R., Choi, H., & Goo, J. M. (2022) · European Radiology · doi:10.1007/s00330-021-08378-8 · Cited by 58
Comprehensive review of potential drugs with anti-pulmonary fibrosis properties
Ma, J., Li, G., Wang, H., & Mo, C. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116282 · Cited by 70
He, S., Li, X., He, Y., Guo, L., Dong, Y., Wang, L., Yang, L., Li, L., Huang, S., Fu, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56223-z · Cited by 78
Bennett, D., Fossi, A., Bargagli, E., Refini, R. M., Pieroni, M., Luzzi, L., Ghiribelli, C., Paladini, P., Voltolini, L., & Rottoli, P. (2015) · Lung · doi:10.1007/s00408-015-9767-x · Cited by 61
Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis
Kreuter, M., Costabel, U., Richeldi, L., Cottin, V., Wijsenbeek, M. S., Bonella, F., Bendstrup, E. M., Maher, T. M., Wachtlin, D., Stowasser, S., et al. (2018) · Respiration · doi:10.1159/000486286 · Cited by 61
Self-citationBellaye, P., Shimbori, C., Upagupta, C., Sato, S., Shi, W., Gauldie, J., Ask, K., & Kolb, M. R. J. (2017) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0252oc · Cited by 59
Self-citationScreening for Lung Cancer: Incidental Pulmonary Parenchymal Findings
Chung, J. H., Richards, J. C., Koelsch, T. L., et al. (2017) · American Journal of Roentgenology · doi:10.2214/ajr.17.19003 · Cited by 56
Checa, J., & Aran, J. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239317 · Cited by 61
Tahara, M., Fujino, Y., Yamasaki, K., Oda, K., Kido, T., Sakamoto, N., Kawanami, T., Kataoka, K., Egashira, R., Hashisako, M., et al. (2021) · Respiratory Research · doi:10.1186/s12931-021-01671-6 · Cited by 67
Targeting Cpt1a-Bcl-2 interaction modulates apoptosis resistance and fibrotic remodeling
Gu, L., Surolia, R., Larson‐Casey, J. L., He, C., Davis, D., Kang, J., Antony, V. B., & Carter, A. B. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-021-00840-w · Cited by 61
Immunological Regulation of Intestinal Fibrosis in Inflammatory Bowel Disease
Bamias, G., Pizarro, T. T., & Cominelli, F. (2021) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izab251 · Cited by 60
Challenges for Clinical Drug Development in Pulmonary Fibrosis
White, E. S., Thomas, M. J., Stowasser, S., & Tetzlaff, K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.823085 · Cited by 68
Self-citationKou, M., Jiao, Y., Li, Z., Wei, B., Li, Y., Cai, Y., & Wei, W. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03720-7 · Cited by 79
A Critical Role for the mTORC2 Pathway in Lung Fibrosis
Chang, W., Wei, K., Ho, L. A., Berry, G. J., Jacobs, S. S., Chang, C. H., & Rosen, G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106155 · Cited by 56
Lee, S. M., Seo, J. B., Oh, S. Y., Kim, T. H., Song, J. W., Lee, S. M., & Kim, N. (2017) · European Radiology · doi:10.1007/s00330-017-5028-0 · Cited by 61
Ntolios, P., Manoloudi, E., Tzouvelekis, A., Bouros, E., Steiropoulos, P., Anevlavis, S., Bouros, D., & Froudarakis, M. E. (2018) · The Clinical Respiratory Journal · doi:10.1111/crj.12777 · Cited by 56
Utility of the six-minute walk test in patients with idiopathic pulmonary fibrosis
LANCASTER, L. H. (2018) · Multidisciplinary Respiratory Medicine · doi:10.1186/s40248-018-0158-z · Cited by 80
Liu, H., Mei, J., Xu, Y. D., Tang, L., Chen, D., Zhu, Y., Huang, S., Webster, T. J., & Ding, H. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s224044 · Cited by 57
Laparoscopic anti-reflux surgery for idiopathic pulmonary fibrosis at a single centre
Raghu, G., Morrow, E. H., Collins, B. F., Ho, L. A., Hinojosa, M. W., Hayes, J. M., Spada, C. A., Oelschlager, B. K., Li, C., Yow, E. S., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.00488-2016 · Cited by 55
Self-citationProgressive fibrosing interstitial lung disease associated with systemic autoimmune diseases
Fischer, A., & Distler, J. H. W. (2019) · Clinical Rheumatology · doi:10.1007/s10067-019-04720-0 · Cited by 63
Roach, K. M., & Bradding, P. (2020) · British Journal of Pharmacology · doi:10.1111/bph.14939 · Cited by 68
“…are pirfenidone and nintedanib, but these are only approved for patients with mild to moderate disease and have considerable side effects resulting in discontinuation or non-adherence and are of limited efficacy (Noble et al., 2011; Ogura et al., 2015; Richeldi et al., 2014b; Takaiwa et al., 2014).”
BackgroundPatient gender bias on the diagnosis of idiopathic pulmonary fibrosis
Assayag, D., Morisset, J., Johannson, K. A., Wells, A. U., & Walsh, S. L. F. (2020) · Thorax · doi:10.1136/thoraxjnl-2019-213968 · Cited by 54
Hermansky–Pudlak syndrome pulmonary fibrosis: a rare inherited interstitial lung disease
Yokoyama, T., & Gochuico, B. R. (2021) · European Respiratory Review · doi:10.1183/16000617.0193-2020 · Cited by 60
Marinescu, D.-C., Raghu, G., Rémy‐Jardin, M., Travis, W. D., Adegunsoye, A., Beasley, M. B., Chung, J. H., Churg, A., Cottin, V., Egashira, R., et al. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.06.013 · Cited by 61
Self-citationThe role of vasculature and angiogenesis in respiratory diseases
Ackermann, M., Werlein, C., Plucinski, E. K., Leypold, S., Kühnel, M., Verleden, S. E., Khalil, H. A., Länger, F. P., Welte, T., Mentzer, S. J., et al. (2024) · Angiogenesis · doi:10.1007/s10456-024-09910-2 · Cited by 76
Hambly, N., Shimbori, C., & Kolb, M. (2015) · Respirology · doi:10.1111/resp.12569 · Cited by 55
Self-citationMukherjee, S., Ayaub, E. A., Murphy, J. S., Lü, C., Kolb, M. R. J., Ask, K., & Janssen, L. J. (2015) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2015-0009oc · Cited by 63
Self-citationLung-Dominant Connective Tissue Disease
Omote, N., Taniguchi, H., Kondoh, Y., et al. (2015) · CHEST Journal · doi:10.1378/chest.14-3174 · Cited by 55
Self-citationIdiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib
Wollin, S. L., Bonella, F., & Stowasser, S. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s76648 · Cited by 72
Self-citationAntifibrotic and anticancer action of 5-ene amino/iminothiazolidinones
Kaminskyy, D. V., den Hartog, G. J. M., Wojtyra, M., Lelyukh, M. I., Gzella, A. K., Bast, A., & Lesyk, R. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.02.011 · Cited by 60
IL-9 Blockade Suppresses Silica-induced Lung Inflammation and Fibrosis in Mice
Sugimoto, N., Suzukawa, M., Nagase, H., Koizumi, Y., Ro, S., Kobayashi, K., Yoshihara, H., Kojima, Y., Asae, K.-H., Hebisawa, A., et al. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0287oc · Cited by 59
Anti‐fibrotic mechanisms of angiotensin AT2‐receptor stimulation
Sumners, C., Peluso, A. A., Haugaard, A. H., Bertelsen, J. B., & Steckelings, U. M. (2019) · Acta Physiologica · doi:10.1111/apha.13280 · Cited by 55
Jacob, J., Aksman, L., Moğulkoç, N., Procter, A., Gholipour, B., Cross, G., Barnett, J. L., Brereton, C. J., Jones, M. G., van Moorsel, C. H. M., et al. (2020) · Thorax · doi:10.1136/thoraxjnl-2019-213865 · Cited by 60
Effectiveness of Proton Pump Inhibitors in Idiopathic Pulmonary Fibrosis
Tran, T., Assayag, D., Ernst, P., & Suissa, S. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.08.2080 · Cited by 60
Genetic Risk Factors for Idiopathic Pulmonary Fibrosis: Insights into Immunopathogenesis
Michalski, J. E., & Schwartz, D. A. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s280958 · Cited by 67
Detection and Early Referral of Patients With Interstitial Lung Abnormalities
Hunninghake, G. M., Goldin, J. G., Kadoch, M. A., Kropski, J. A., Rosas, I. O., Wells, A. U., Yadav, R., Lazarus, H. M., Abtin, F. G., Corte, T. J., et al. (2021) · CHEST Journal · doi:10.1016/j.chest.2021.06.035 · Cited by 58
Self-citationWuyts, W. A., Dahlqvist, C., Slabbynck, H., Schlesser, M., Gusbin, N., Compere, C., Maddens, S., Kirchgaessler, K.-U., Bartley, K., & Bondue, B. (2018) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2018-000331 · Cited by 54
“Similarly, in the INPULSIS trials of nintedanib (INPULSIS 1 and 2: 52 Weeks, Double Blind, Randomized, Placebo-controlled Trials Evaluating the Effect of Oral BIBF 1120, 150 mg Twice Daily, on Annual Forced Vital Capacity Decline, in Patients With Idiopathic Pulmonary Fibrosis; NCT01335464 and NCT01335477), nintedanib…”
MethodPulmonary CCR2+CD4+T cells are immune regulatory and attenuate lung fibrosis development
Milger, K., Yu, Y., Brudy, E., Irmler, M., Skapenko, A., Mayinger, M. C., Lehmann, M., Beckers, J., Reichenberger, F., Behr, J., et al. (2017) · Thorax · doi:10.1136/thoraxjnl-2016-208423 · Cited by 66
Patient Registries in Idiopathic Pulmonary Fibrosis
Culver, D. A., Behr, J., Belperio, J. A., Corte, T. J., de Andrade, J. A., Flaherty, K. R., Gulati, M., Huie, T. J., LANCASTER, L. H., Roman, J., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201902-0431ci · Cited by 58
Self-citationNeighborhood-Level Disadvantage Impacts on Patients with Fibrotic Interstitial Lung Disease
Goobie, G. C., Ryerson, C. J., Johannson, K. A., Schikowski, E., Zou, R. H., Khalil, N., Marcoux, V. S., Assayag, D., Manganas, H., Fisher, J. H., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202109-2065oc · Cited by 60
Self-citationUegami, W., Bychkov, A., Ozasa, M., Uehara, K., Kataoka, K., Johkoh, T., Kondoh, Y., Sakanashi, H., & Fukuoka, J. (2022) · Modern Pathology · doi:10.1038/s41379-022-01025-7 · Cited by 54
Sullivan, D. I., & Ascherman, D. P. (2024) · Current Rheumatology Reports · doi:10.1007/s11926-024-01155-8 · Cited by 66
Asbestosis and environmental causes of usual interstitial pneumonia
Gulati, M., & Redlich, C. A. (2015) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000144 · Cited by 63
Yoon, P. O., Park, J. W., Lee, C., Kim, S. H., Kim, H., Ko, Y., Bae, S. J., Yun, S., Park, J. H., Kwon, T., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.693671 · Cited by 57
“Currently only 2 drugs are approved as therapeutic drugs, but they only delay the progress of the disease with improved lung function (43-45).”
BackgroundWhen to start and when to stop antifibrotic therapies
Torrisi, S. E., Pavone, M., Vancheri, A., & Vancheri, C. (2017) · European Respiratory Review · doi:10.1183/16000617.0053-2017 · Cited by 56
Synergistic role of HSP90α and HSP90β to promote myofibroblast persistence in lung fibrosis
Bellaye, P.-S., Shimbori, C., Yanagihara, T., Carlson, D. A., Hughes, P., Upagupta, C., Sato, S., Wheildon, N., Haystead, T., Ask, K., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.00386-2017 · Cited by 54
Self-citationSafer approaches to therapeutic modulation of TGF-β signaling for respiratory disease
Lachapelle, P., Li, M., Douglass, J. A., & Stewart, A. G. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.02.010 · Cited by 56
Swigris, J. J., Wilson, H., Esser, D., Conoscenti, C., Stansen, W., Leidy, N. K., & Brown, K. K. (2018) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2018-000278 · Cited by 62
Self-citationConnective tissue disease-associated interstitial lung disease
Oliveira, R. P., Ribeiro, R., Melo, L., Grima, B., Oliveira, S., & Alves, J. D. (2020) · Pulmonology · doi:10.1016/j.pulmoe.2020.01.004 · Cited by 57
Hobbs, S., Chung, J. H., Leb, J. S., Kaproth-Joslin, K. A., & Lynch, D. A. (2021) · Radiology Cardiothoracic Imaging · doi:10.1148/ryct.2021200279 · Cited by 62
Impact of Depression on Patients With Idiopathic Pulmonary Fibrosis
Τzouvelekis, Α., Karampitsakos, Τ., Kourtidou, S., Bouros, E., Tzilas, V., Katsaras, M., Antonou, C., Dassiou, M., & Bouros, D. E. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00029 · Cited by 54
Suzuki, Y., Aono, Y., Kono, M., Hasegawa, H., Yokomura, K., Naoi, H., Hozumi, H., Karayama, M., Furuhashi, K., Enomoto, N., et al. (2020) · Respirology · doi:10.1111/resp.13943 · Cited by 58
Islam, M. S., Afrin, S., Singh, B., Jayes, F. L., Brennan, J. T., Borahay, M. A., Leppert, P. C., & Segars, J. H. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.475 · Cited by 54
Cottin, V., Martinez, F. J., Jenkins, R. G., Belperio, J. A., Kitamura, H., Molina-Molina, M., Tschoepe, I., Coeck, C., Lievens, D., & Costabel, U. (2022) · Respiratory Research · doi:10.1186/s12931-022-01974-2 · Cited by 53
Self-citationThe microtubule cytoskeleton: An old validated target for novel therapeutic drugs
Lafanéchère, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.969183 · Cited by 55
“Nintedanib is clinically indicated to treat idiopathic pulmonary fibrosis (Richeldi et al., 2014; Crestani et al., 2019).”
BackgroundTirelli, C., Pesenti, C., Miozzo, M. R., Mondoni, M., Fontana, L., & Centanni, S. (2022) · Diagnostics · doi:10.3390/diagnostics12123107 · Cited by 57
“Two drugs, nintedanib and pirfenidone, have been approved for the treatment of the disease, since in clinical trials and observational studies they have been shown to slow down the progression of the disease, without, however, being able to stop or cure it [4,5].”
BackgroundMia, M. M., Ghani, S. A. B. A., Cibi, D. M., Bogireddi, H., Nilanthi, U., Selvan, A., Shiu, W., & Singh, M. K. (2025) · European Respiratory Journal · doi:10.1183/13993003.01544-2023 · Cited by 74
Kaunisto, J., Kelloniemi, K., Sutinen, E., Hodgson, U., Piilonen, A., Kaarteenaho, R., Mäkitaro, R., Purokivi, M., Lappi-Blanco, E., Saarelainen, S., et al. (2015) · BMC Pulmonary Medicine · doi:10.1186/s12890-015-0074-3 · Cited by 53
CT in Idiopathic Pulmonary Fibrosis: Diagnosis and Beyond
Gruden, J. F. (2016) · American Journal of Roentgenology · doi:10.2214/ajr.15.15674 · Cited by 53
“CT and Clinical Trials Recent treatment trials, including those that led to the approval of pirfenidone and nintedanib for the treatment of IPF, used CT primarily as a diagnostic tool for study entry in patients with CT findings, as specified in Table 1 [67, 68].”
BackgroundMethodEarly clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres
Toellner, H., Hughes, G., Beswick, W., Crooks, M. G., Donaldson, C., Forrest, I., Hart, S. P., Leonard, C. T., Major, M., Simpson, A. J., et al. (2017) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0172-3 · Cited by 54
The need for a holistic approach for SSc-ILD – achievements and ambiguity in a devastating disease
Hoffmann‐Vold, A., Allanore, Y., Bendstrup, E. M., Bruni, C., Distler, O., Maher, T. M., Wijsenbeek, M. S., & Kreuter, M. (2020) · Respiratory Research · doi:10.1186/s12931-020-01459-0 · Cited by 63
Tian, L., Gao, J., Garcia, I. M., Chen, H. J., Castaldi, A., & Chen, Y. (2020) · Wiley Interdisciplinary Reviews Developmental Biology · doi:10.1002/wdev.399 · Cited by 58
“The etiology and pathogenesis of this disease are unclear (Lederer & Martinez, 2018; Noble, Barkauskas, & Jiang, 2012; Ryu et al., 2014) and existing drugs can only slow disease progression (King Jr. et al., 2014; Richeldi et al., 2014).”
BackgroundSH2 Domain–Containing Phosphatase-2 Is a Novel Antifibrotic Regulator in Pulmonary Fibrosis
Tzouvelekis, A., Yu, G., Cardenas, C. L. L., Herazo‐Maya, J. D., Wang, R., Woolard, T., Zhang, Y., Sakamoto, K., Lee, H., Yi, J.-S., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201602-0329oc · Cited by 54
Hamada, S., Ichiyasu, H., Ikeda, T., Inaba, M., Kashiwabara, K., Sadamatsu, T., Sato, N., Akaike, K., Okabayashi, H., Saruwatari, K., et al. (2019) · BMC Pulmonary Medicine · doi:10.1186/s12890-019-0838-2 · Cited by 53
Takei, R., Brown, K. K., Yamano, Y., Kataoka, K., Yokoyama, T., Matsuda, T., Kimura, T., Suzuki, A., Furukawa, T., Fukuoka, J., et al. (2022) · Respirology · doi:10.1111/resp.14245 · Cited by 62
“The prognosis of IPF is poor but available antifibrotic agents reduce the annual rate of decline in the forced vital capacity (FVC) and prolong survival.(1,2,7,8) Recently, several studies reported the effectiveness of antifibrotic agents in patients with non-IPF FILD, in whom progression of the underlying disease had…”
BackgroundSelf-citationShintani, Y., Kimura, T., Funaki, S., Ose, N., Kanou, T., & Fukui, E. (2023) · Cancers · doi:10.3390/cancers15020335 · Cited by 57
“Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pulmonary disease and is known to increase the risk of NSCLC; thus, there are multiple common genetic, molecular, and cellular processes that connect lung fibrosis with NSCLC, including fibroblast activation [122].”
BackgroundInfluentialIdiopathic Pulmonary Fibrosis and Post-COVID-19 Lung Fibrosis: Links and Risks
Patrucco, F., Solidoro, P., Gavelli, F., Apostolo, D., & Bellan, M. (2023) · Microorganisms · doi:10.3390/microorganisms11040895 · Cited by 63
“Even though many efforts have been made to better understand the pathogenesis and to develop new antifibrotic agents able to reduce the incidence of AE events [36,37], AE-IPF prognosis is still poor and precedes nearly 40% of IPF deaths, with a median survival following an AE of three to four months [27].”
Oh, A. S., Lynch, D. A., Swigris, J. J., Baraghoshi, D., Dyer, D. S., Hale, V. A., Koelsch, T. L., Marrocchio, C., Parker, K. N., Teague, S. D., et al. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202301-084oc · Cited by 62
Self-citationMackintosh, J. A., Keir, G. J., Troy, L. K., Holland, A. E., Grainge, C., Chambers, D. C., Sandford, D., Jo, H. E., Glaspole, I., WILSHER, M. L., et al. (2024) · Respirology · doi:10.1111/resp.14656 · Cited by 60
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.